

**Zoono Group Limited (ASX: ZNO)
ASX ANNOUNCEMENT**

28th February 2020

Zoono Tests Successfully Against Coronavirus COVID-19

Zoono Group Limited (ASX:ZNO) is pleased to advise that it has today received the report for the laboratory tests undertaken against COVID-19. The results show that Zoono's Z-71 Microbe Shield (the same Zoono technology used in Zoono hand sanitiser) is > 99.99% effective against COVID-19.

COVID-19 has become a global concern, in particular as it has been shown to survive on surfaces for up to 9 days. Zoono products have been successfully tested against a variety of pathogens for up to 30 days on surfaces and 24 hours on hands.

Whilst Zoono had been previously tested against bovine coronavirus (the nominated surrogate for MERS), this latest strain required new testing.

Two separate tests were completed to EN Standard 14476:2013+A2:2019. The first was against Vaccinia, sometimes referred to as the 'mother ship' of double enveloped viruses (that are particularly hard to inactivate); with the subsequent test against the nominated (and globally accepted) surrogate for COVID-19, feline coronavirus.

EN14476 is the European Standard that applies to products within the medical area including hygienic hand rubs, hygienic hand wash, instrument disinfection by immersion, surface disinfection by wiping, spraying, flooding or other means.

RESULTS:

The test against Vaccinia confirmed efficacy of > 4Log (greater than 99.99% efficacy) for Zoono Z-71 Microbe Shield (the same Zoono technology used in Zoono Hand Sanitiser).

The second test against the COVID-19 surrogate, feline coronavirus, confirmed efficacy at 4.33Log (greater than 99.99% efficacy).

The members of the family Coronaviridae are enveloped and have positive sense RNA genome. Coronaviruses have a distinct morphology with an outer 'corona' of embedded envelope spikes. These viruses cause a broad spectrum of animal and human disease and are particularly difficult to inactivate.

Zoono is very pleased with the results which further demonstrates the ability of the Zoono technology to be part of the solution to prevent and protect against the spread of the COVID-19 Virus.

This announcement has been authorised and approved for release to ASX by the Managing Director of Zoono Group Limited.

For further information, please contact:

Zoono Group Limited

Paul Hyslop

CEO

M: +64 21 659977

E: paul.hyslop@zoono.com.

About Zoono

Zoono Group Limited is a global biotech company that develops, manufactures and distributes a suite of scientifically-validated, long-lasting and environmentally-friendly antimicrobial solutions. Zoono's mission is to improve health and well-being through innovative, safe, non-toxic and durable germ protection.

Zoono produces sprays, wipes and foams suited for skin care, surface sanitisers, and mould remediation treatments. The products are based on the 'zoono molecule', a unique antimicrobial molecule that bonds to any surface and kills pathogens including bacteria, viruses, algae, fungi and mould.

Zoono's products have received numerous regulatory approvals and the company's technology claims are supported by independent testing conducted in laboratories worldwide. Zoono is headquartered in New Zealand and its products are available globally.

To learn more, please visit: www.zoono.com